11,576 results match your criteria Psoriatic Arthritis


Biologics and small molecules in the management of psoriatic arthritis: Reproduction related issues in female and male patients.

Expert Rev Clin Pharmacol 2021 May 13:1-11. Epub 2021 May 13.

Department of Rheumatology, Sorlandet Hospital, Kristiansand, Norway.

STRACT: Psoriatic arthritis (PsA) is the musculoskeletal manifestation of psoriatic disease, an inflammatory systemic disease with a high incidence in the reproductive years. Biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) as well as 'small molecules', are increasingly used to treat subtypes of PsA. Safety concerns exist in the field of fertility for PsA patients since the literature shows discordant results toward the influence of anti-psoriatic drugs. Read More

View Article and Full-Text PDF

Functional study of TNF-α promoter polymorphisms in psoriasis.

Ital J Dermatol Venerol 2021 May 13. Epub 2021 May 13.

Pediatric Laboratory, Department of Pediatrics, Regina Margherita Children's Hospital, University of Turin, Turin, Italy -

Background: TNF-α is an important mediator in the pathogenesis of psoriasis and polymorphisms influence its transcription and could be implicated in psoriasis risk and modify certain aspects of disease, such as age at onset of psoriasis vulgaris and disease severity. Six TNF-α single nucleotide polymorphisms (SNPs) in promoter region has been identified and studied but with discordant results. The aim of this study was to evaluate whether the polymorphisms in TNF-α (-238 (rs361525), -308 (rs1800629), -857 (rs1799724), -1031 (rs1799964)) are associated with gravity, prurity, early onset or response to drug therapy in psoriasis in Caucasian Italian patients. Read More

View Article and Full-Text PDF

The first non-radiographic axial spondyloarthrits with COVID-19.

Immun Inflamm Dis 2021 May 12. Epub 2021 May 12.

The Rheumatology Group, South Charleston, West Virginia, USA.

Background: Case report of a 21-year-old female developing non-radiographic axialspondyloarthritis in the setting of a preceding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We felt this was a unique case as some cases of psoriatic arthropathy and reactive arthropathy but none, to our knowledge of non-radiographic axial spondyloarthritis.

Case Presentation: Twenty one-year-old female presented in June 2020 with inflammatory symptoms with general work-up per primary care provider being negative. Read More

View Article and Full-Text PDF

Prevalence and severity of coronary artery disease linked to prognosis in psoriasis and psoriatic arthritis patients: A multi-centre cohort study.

J Intern Med 2021 May 12. Epub 2021 May 12.

Department of Cardiology, Gødstrup Hospital, Herning, Denmark.

Objectives: 1) To estimate the prevalence and severity of coronary artery disease and 2) to assess the risk of cardiovascular events and mortality, in patients with psoriasis and psoriatic arthritis (PsA) in a large-scale cohort of patients referred to coronary computed tomography angiography (CTA).

Methods: This was a cross-sectional study with follow-up of 46,022 patients based on data from a Danish national CTA registry. Exposures was defined as psoriasis or PsA. Read More

View Article and Full-Text PDF

Patients with different types of arthritis may be at risk for major depression: results from the National Health and Nutrition Examination Survey 2007-2018.

Ann Palliat Med 2021 Apr 22. Epub 2021 Apr 22.

Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing, China.

Background: Arthritis is one of the common causes of physical pain and disability, which often makes patients fall into major depression. However, the correlation between arthritis and major depression, and how different types of arthritis correspond to major depression remain to be explored. The purpose of this study is to explore the relationship between arthritis and major depression. Read More

View Article and Full-Text PDF

Comparison of Behavioral Risk Factors and Cardiometabolic Comorbidities of Psoriatic Arthritis and Psoriasis: A Case-Control Study in Chinese Patients.

Ther Clin Risk Manag 2021 3;17:397-404. Epub 2021 May 3.

Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.

Purpose: Comparison of risk factors and comorbidities could help indicate the underlying mechanisms of diseases. This study aimed to compare behavioral factors and cardiometabolic comorbidities of PsA/psoriasis versus healthy controls to implicate the similarities and differences in potential pathogenic mechanisms for further research.

Patients And Methods: A case-control study in Chinese patients with PsA or psoriasis and healthy controls was conducted. Read More

View Article and Full-Text PDF

Brodalumab in the treatment of psoriatic arthritis - the latest reports.

Reumatologia 2021 27;59(2):126-127. Epub 2021 Apr 27.

Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.

View Article and Full-Text PDF

A Virtual Reality-Based App to Educate Health Care Professionals and Medical Students About Inflammatory Arthritis: Feasibility Study.

JMIR Serious Games 2021 May 11;9(2):e23835. Epub 2021 May 11.

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Background: Inflammatory arthritides (IA) such as rheumatoid arthritis or psoriatic arthritis are disorders that can be difficult to comprehend for health professionals and students in terms of the heterogeneity of clinical symptoms and pathologies. New didactic approaches using innovative technologies such as virtual reality (VR) apps could be helpful to demonstrate disease manifestations as well as joint pathologies in a more comprehensive manner. However, the potential of using a VR education concept in IA has not yet been evaluated. Read More

View Article and Full-Text PDF

Body composition in patients with psoriatic arthritis and changes during interleukin 12/23 inhibition.

Arthritis Care Res (Hoboken) 2021 May 10. Epub 2021 May 10.

Univ. Lille, CHU Lille, Department of Rheumatology, 59000, Lille, France.

Objective: Little is known about body composition in patients with PsA. We compared body composition parameters in PsA patients and healthy controls, and then investigated the effects of ustekinumab (UST) on body composition in patients with PsA.

Methods: At baseline, 30 PsA patients were compared cross-sectionnally with 60 non-PsA healthy controls matched for age, sex, menopausal status and body mass index. Read More

View Article and Full-Text PDF

Risk of Hospitalized Serious Infection After Initiating Ustekinumab or Other Biologics for Psoriasis or Psoriatic Arthritis.

Arthritis Care Res (Hoboken) 2021 May 10. Epub 2021 May 10.

Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.

Objective: To compare the risk of serious infections requiring hospitalization in patients with psoriasis (PsO) or psoriatic arthritis (PsA) initiating ustekinumab versus other biologics or apremilast.

Methods: In this multi-database cohort study, we identified patients with PsO/PsA who initiated adalimumab, apremilast, certolizumab, etanercept, golimumab, ixekizumab, secukinumab, or ustekinumab between 2009 and 2018. The primary outcome was hospitalized serious infections including bacterial, viral, or opportunistic infections. Read More

View Article and Full-Text PDF

COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database.

Fundam Clin Pharmacol 2021 May 10. Epub 2021 May 10.

RECIF, Amiens-Picardie University Medical Center, F-80054, Amiens, France.

Background: To determine whether the use of disease-modifying antirheumatic drugs (DMARDs) is linked to the risk of COVID-19 among patients with inflammatory rheumatic diseases (IRDs).

Methods: We performed a disproportionality analysis of the World Health Organization pharmacovigilance database between January 1, 2020, and June 10, 2020. The frequency of COVID-19 reports for all DMARD classes identified was compared with that for all other reports for all other drugs and quoted as the reporting odds ratio (ROR) [95% confidence interval (CI)]. Read More

View Article and Full-Text PDF

Cardiovascular disease and depression in psoriatic arthritis: Multidimensional comorbidities requiring multidisciplinary management.

Authors:
Ho So Lai-Shan Tam

Best Pract Res Clin Rheumatol 2021 May 5:101689. Epub 2021 May 5.

Division of Rheumatology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong. Electronic address:

Psoriatic arthritis (PsA) is a chronic systemic inflammatory disease. The control of joint and skin manifestations has improved tremendously with the advent of the targeted therapies in the past decade. However, the occurrence of PsA is frequently accompanied by metabolic diseases, cardiovascular diseases (CVD), and depression. Read More

View Article and Full-Text PDF

2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis.

Ann Rheum Dis 2021 May 7. Epub 2021 May 7.

National Rheumatoid Arthritis Society, Littlewick Green, UK.

Background: An important but often insufficient aspect of care in people with inflammatory arthritis (IA) is empowering patients to acquire a good understanding of their disease and building their ability to deal effectively with the practical, physical and psychological impacts of it. Self-management skills can be helpful in this regard.

Objectives: To develop recommendations for the implementation of self-management strategies in IA. Read More

View Article and Full-Text PDF

JAK1 selective inhibitors for the treatment of spondyloarthropathies.

Rheumatology (Oxford) 2021 May;60(Supplement_2):ii39-ii44

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, UK.

As our understanding of the pathogenesis of SpA improves, focus has turned to the role janus kinase (JAK)-mediated signal transduction and inhibiting its actions as a therapeutic mechanism. Small molecule inhibitors of JAK exist, with variable selectivity for the different JAK isoforms. Less selective JAK inhibitors have variable efficacy and safety profiles, prompting the investigation of selective JAK1 inhibition. Read More

View Article and Full-Text PDF

Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series.

JAAD Case Rep 2021 May 13;11:84-89. Epub 2021 Mar 13.

Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain.

View Article and Full-Text PDF

Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic.

Int J Rheum Dis 2021 May 4. Epub 2021 May 4.

Department of Rheumatology, BSM Medical University, Dhaka, Bangladesh.

Aim: To update previous guidance of the Asia Pacific League of Associations for Rheumatology (APLAR) on the management of patients with rheumatic and musculoskeletal diseases (RMD) during the coronavirus disease 2019 (COVID-19) pandemic.

Methods: Research questions were formulated focusing on diagnosis and treatment of adult patients with RMD within the context of the pandemic, including the management of RMD in patients who developed COVID-19. MEDLINE was searched for eligible studies to address the questions, and the APLAR COVID-19 task force convened 2 meetings through video conferencing to discuss its findings and integrate best available evidence with expert opinion. Read More

View Article and Full-Text PDF

Use of telemedicine during the COVID-19 pandemic in patients with inflammatory arthritis: a retrospective study on feasibility and impact on patient-reported outcomes in a real-life setting.

Rheumatol Int 2021 May 4. Epub 2021 May 4.

Division of Rheumatology, Multispecialist Medical Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Close follow-up is mandatory in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). During the Coronavirus Disease 2019 (COVID-19) pandemic, rheumatological care was rapidly reorganized during the first peak from March 1, 2020 to May 31, 2020, and all patients with RA, PsA, and AS being treated with a subcutaneous biologic disease-modifying anti-rheumatic drug or oral targeted synthetic disease-modifying anti-rheumatic drug were followed remotely. A retrospective database analysis of these 431 patients before and after this period is presented herein. Read More

View Article and Full-Text PDF

Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort.

Rheumatol Int 2021 May 4. Epub 2021 May 4.

Department of Medical Biochemistry, Oslo University Hospital-Radiumhospitalet, Box 4953 Nydalen, 0424, Oslo, Norway.

The aim of the study was to  assess RF cross-reactivity to animal antibodies used in immunoassays, and to test if selected commercial immunoassays are vulnerable to interference from RF, causing false test results. Our study included samples from patients with RF-positive rheumatoid arthritis (RA) and controls (patients with RF-negative RA and psoriatic arthritis), included in an early arthritis-cohort. Reactivity to mouse IgG1, mouse IgG2a, rabbit IgG, bovine IgG, sheep/goat IgG and human IgG was analysed using in-house interference assays. Read More

View Article and Full-Text PDF

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

JAMA 2021 05;325(17):1744-1754

Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.

Importance: Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to standard therapy to maximize efficacy and safety of infliximab and other biological drugs. However, whether proactive TDM improves clinical outcomes when implemented at the time of drug initiation, compared with standard therapy, remains unclear.

Objective: To assess whether TDM during initiation of infliximab therapy improves treatment efficacy compared with standard infliximab therapy without TDM. Read More

View Article and Full-Text PDF

JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.

Expert Rev Clin Immunol 2021 May 13:1-15. Epub 2021 May 13.

Division of Rheumatology, University of Alberta, Edmonton, Alberta, Canada.

Introduction: Psoriatic arthritis (PsA) and spondyloarthritis (SpA) are inflammatory arthritides associated with progressive damage, deformity and morbidity. Janus kinase (JAK) inhibitors block JAKs, cytoplasmic protein tyrosine kinases important in signal transduction and immune processes that are currently being studied as synthetic disease modifying anti-rheumatic drugs (tsDMARDs) in psoriatic arthritis and spondyloarthritis.

Areas Covered: This review evaluates published phase 2 and 3 clinical trial data for JAK kinase inhibitors for psoriatic arthritis and spondyloarthritis. Read More

View Article and Full-Text PDF

Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor.

J Orthop Surg (Hong Kong) 2021 May-Aug;29(2):23094990211012286

Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

Objectives: The patient of severe psoriatic arthritis (PsA) is mainly treated with oral methotrexate, ciclosporin, and anti-tumor necrosis factor-alpha inhibitors (TNFi). Recently, anti-interleukin-17A inhibitors (IL-17Ai) have been used in the treatment of PsA. This study aimed to evaluate the efficacy and safety of IL-17Ai in Japanese patients with PsA compared with those of TNFi. Read More

View Article and Full-Text PDF

The Role of PDE8 in T Cell Recruitment and Function in Inflammation.

Front Cell Dev Biol 2021 16;9:636778. Epub 2021 Apr 16.

Department of Immunology, UConn Health, Farmington, CT, United States.

Inhibitors targeting cyclic nucleotide phosphodiesterases (PDEs) expressed in leukocytes have entered clinical practice to treat inflammatory disorders, with three PDE4 inhibitors currently in clinical use as therapeutics for psoriasis, psoriatic arthritis, atopic dermatitis and chronic obstructive pulmonary disease. In contrast, the PDE8 family that is upregulated in pro-inflammatory T cells is a largely unexplored therapeutic target. It was shown that PDE8A plays a major role in controlling T cell and breast cancer cell motility, including adhesion to endothelial cells under physiological shear stress and chemotaxis. Read More

View Article and Full-Text PDF

SARS-CoV-2 Infection Induces Psoriatic Arthritis Flares and Enthesis Resident Plasmacytoid Dendritic Cell Type-1 Interferon Inhibition by JAK Antagonism Offer Novel Spondyloarthritis Pathogenesis Insights.

Front Immunol 2021 15;12:635018. Epub 2021 Apr 15.

Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom.

Objective: Bacterial and viral infectious triggers are linked to spondyloarthritis (SpA) including psoriatic arthritis (PsA) development, likely dendritic cell activation. We investigated spinal entheseal plasmacytoid dendritic cells (pDCs) toll-like receptor (TLR)-7 and 9 activation and therapeutic modulation, including JAK inhibition. We also investigated if COVID-19 infection, a potent TLR-7 stimulator triggered PsA flares. Read More

View Article and Full-Text PDF

Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 to 2020.

Clin Rheumatol 2021 May 2. Epub 2021 May 2.

Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, USA.

Objectives: To compare healthcare resource utilization and costs among patients with psoriasis, psoriatic arthritis (PsA), and a control group of patients without psoriasis and PsA in the USA.

Methods: The IBM® MarketScan® Commercial Database was used to identify three adult patient groups from 1/1/2009 through 4/30/2020: (1) Psoriasis: ≥ 2 diagnoses ≥ 30 days apart for psoriasis (no PsA diagnoses); (2) PsA: ≥ 2 diagnoses for PsA; (3) Control: no psoriasis or PsA diagnoses in their entire claims records. Patients with comorbid rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, or ulcerative colitis were excluded from the analyses. Read More

View Article and Full-Text PDF

Management of particular clinical situations in psoriatic arthritis: an expert's recommendation document based on systematic literature review and extended Delphi process.

Rheumatol Int 2021 May 2. Epub 2021 May 2.

Servicio de Reumatología, Hospital Universitari Arnau de Vilanova, Lleida, Spain.

To establish practical recommendations for the management of patients with psoriatic arthritis (PsA) with particular clinical situations that might lead to doubts in the pharmacological decision-making. A group of six expert rheumatologists on PsA identified particular clinical situations in PsA. Then, a systematic literature review (SLR) was performed to analyse the efficacy and safety of csDMARDs, b/tsDMARDs in PsA. Read More

View Article and Full-Text PDF

Development of an instrument for patient self-assessment in psoriatic arthritis.

J Rheumatol 2021 May 1. Epub 2021 May 1.

Rheumatology Department, Bradford Teaching Hospitals Foundation Trust, Bradford, UK; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. Funding: No specific funding was received from any bodies in the public, commercial or notfor- profit sectors to carry out the work described in this article. Address correspondence to Dr Philip S. Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email:

Objective: Due to the recent pandemic, in person scheduled rheumatology appointments in many countries have been reserved for urgent cases only. Here we report the development of a multidimensional, patient completed disease assessment tool for use in psoriatic arthritis (PsA).

Methods: A focus group development and education method was used, followed by a paired observation design to assess feasibility and validity. Read More

View Article and Full-Text PDF

Pooled Safety Results Through One Year of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis.

J Rheumatol 2021 May 1. Epub 2021 May 1.

Memorial University of Newfoundland, St. Johns, Newfoundland, Canada; University of Rochester, Rochester, NY, USA; University of Leeds, Leeds, United Kingdom; Geneva University Hospitals, Geneva, Switzerland; Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, WA, USA; Icahn Medical School/Mount Sinai, New York, NY, USA; Janssen Scientific Affairs, LLC, Horsham, PA, USA; Janssen Research & Development, LLC, San Diego, CA, USA; Janssen Research & Development, LLC, Spring House, PA, USA; University of Pennsylvania School of Medicine, Philadelphia, PA, USA; Janssen Global Services, LLC, Horsham, PA, USA; University of Glasgow, Glasgow, United Kingdom. CT Ritchlin received research support (AbbVie, Amgen, UCB Pharma); consultant fees (AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB Pharma) P Rahman received research support (Janssen, Novartis); consultant fees (Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, UCB); speaker bureau support (AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, UCB) PS Helliwell received consulting fees (Eli Lilly) and fees for educational services (Amgen, Janssen, Novartis, Pfizer). W-H Boehncke received research support (Pfizer); consulting fees and speaker bureau support (AbbVie, Almirall, Celgene, Janssen, Leo, Lilly, Novartis, UCB) IB McInnes received research support (Astra Zeneca, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Novartis, UCB); consultant fees (AbbVie, Bristol-Myers Squibb, Boehringer-Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, UCB). AB Gottlieb received research support (Janssen-Ortho, Boehringer Ingelheim, Incyte, Janssen, Novartis, Pharmaceutical Industries, UCB, Xbiotech); honoraria (Amgen, Bristol Myers Squibb, Celgene, Janssen Biotech, Janssen-Ortho, LEO Pharma, Novartis, UCB); consultant fees (AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, Pharmaceutical Industries); and stock options (XBiotech). PJ Mease received research support, consulting fees, and speaker bureau support (AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB) S Kafka, was an employee of Janssen Scientific Affairs, LLC, at the time this work was performed; A Kollmeier, E Hsia, XL Xu, S Sheng, P Agarwal, B Zhou, P Ramachandran, and Y Zhuang are employees of Janssen Research & Development, LLC; and M Shawi is an employee of Janssen Global Services, LLC, and own stock or stock options in Johnson & Johnson. Address correspondence to: Dr. Proton Rahman, 154 LeMarchant Rd, St. Clare's Mercy Hospital, St. John's Newfoundland, Canada A1C 5B8.

Objective: Evaluate safety of guselkumab (monoclonal antibody targeting IL-23p19) in psoriatic arthritis (PsA) patients through 1year (1Y) of the Phase-3 DISCOVER-1&2 trials.

Methods: Patients with active PsA (N=1120; biologic-naïve except the118 TNFi-treated DISCOVER-1 patients) were randomized to subcutaneous guselkumab 100 mg every 4 weeks (Q4W) or at Week 0, Week4, then Q8W; or placebo. At Week24, placebo patients switched to guselkumab 100 mg Q4W. Read More

View Article and Full-Text PDF

Recommendations of the Mexican College of Rheumatology for the management of psoriatic arthritis.

Reumatol Clin 2021 Apr 27. Epub 2021 Apr 27.

Facultad de Medicina y Ciencias Biomédicas, Universidad Autónoma de Chihuahua, Chihuahua, México. Electronic address:

Psoriatic arthritis is a chronic systemic inflammatory disease that affects the skin, musculoskeletal structures and other organs and systems compromising functionality, quality of life and reducing the life expectancy of patients. It is a complex disease that requires specialist and timely care and management. The alternatives for treating the manifestations of psoriatic arthritis have increased and the effect of the different agents on specific manifestations has been clarified in recent studies. Read More

View Article and Full-Text PDF